US5663180A
(en)
*
|
1983-10-29 |
1997-09-02 |
G.D. Searle & Co. |
Substituted cyclopentenes for the treatment of inflammation
|
US6492413B2
(en)
*
|
1993-01-15 |
2002-12-10 |
G.D. Searle & Co. |
3.4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
|
CA2243199C
(en)
*
|
1993-01-15 |
2005-08-02 |
G.D. Searle & Co. |
Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
|
GB9420616D0
(en)
*
|
1994-10-12 |
1994-11-30 |
Merck Sharp & Dohme |
Method, compositions and use
|
US6090834A
(en)
*
|
1993-05-21 |
2000-07-18 |
G.D. Searle & Co. |
Substituted oxazoles for the treatment of inflammation
|
US5474995A
(en)
*
|
1993-06-24 |
1995-12-12 |
Merck Frosst Canada, Inc. |
Phenyl heterocycles as cox-2 inhibitors
|
US5840746A
(en)
*
|
1993-06-24 |
1998-11-24 |
Merck Frosst Canada, Inc. |
Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
|
GB9602877D0
(en)
*
|
1996-02-13 |
1996-04-10 |
Merck Frosst Canada Inc |
3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
|
CN1143365A
(zh)
*
|
1994-01-10 |
1997-02-19 |
麦克弗罗斯特(加拿大)有限公司 |
作为cox-2抑制剂的苯基杂环类化合物
|
EP1125932A3
(de)
*
|
1994-07-27 |
2001-08-29 |
G.D. Searle & Co. |
Substituierte Thiazole zur Behandlung von Entzündungen
|
US5620999A
(en)
*
|
1994-07-28 |
1997-04-15 |
Weier; Richard M. |
Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
|
US6613789B2
(en)
|
1994-07-28 |
2003-09-02 |
G. D. Searle & Co. |
Heterocyclo-substituted imidazoles for the treatment of inflammation
|
US5616601A
(en)
*
|
1994-07-28 |
1997-04-01 |
Gd Searle & Co |
1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
|
US6426360B1
(en)
*
|
1994-07-28 |
2002-07-30 |
G D Searle & Co. |
4,5-substituted imidazolyl compounds for the treatment of inflammation
|
US6239172B1
(en)
*
|
1997-04-10 |
2001-05-29 |
Nitrosystems, Inc. |
Formulations for treating disease and methods of using same
|
GB2294879A
(en)
*
|
1994-10-19 |
1996-05-15 |
Merck & Co Inc |
Cylcooxygenase-2 Inhibitors
|
CA2200462A1
(en)
*
|
1994-10-27 |
1996-05-09 |
Merck Frosst Canada Inc. |
Stilbene derivatives useful as cyclooxygenase-2 inhibitors
|
JP2636819B2
(ja)
|
1994-12-20 |
1997-07-30 |
日本たばこ産業株式会社 |
オキサゾール系複素環式芳香族化合物
|
JPH10511089A
(ja)
*
|
1994-12-21 |
1998-10-27 |
メルク フロスト カナダ インコーポレーテツド |
Cox−2阻害剤としてのジアリール−2−(5h)−フラノン
|
JP3267300B2
(ja)
*
|
1995-02-13 |
2002-03-18 |
ジー.ディー.サール アンド カンパニー |
炎症の治療のための置換イソオキサゾール
|
US5633272A
(en)
*
|
1995-02-13 |
1997-05-27 |
Talley; John J. |
Substituted isoxazoles for the treatment of inflammation
|
US5691374A
(en)
*
|
1995-05-18 |
1997-11-25 |
Merck Frosst Canada Inc. |
Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
|
US5643933A
(en)
*
|
1995-06-02 |
1997-07-01 |
G. D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6512121B2
(en)
|
1998-09-14 |
2003-01-28 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
WO1996038418A1
(en)
|
1995-06-02 |
1996-12-05 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6515014B2
(en)
|
1995-06-02 |
2003-02-04 |
G. D. Searle & Co. |
Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6156776A
(en)
*
|
1995-06-08 |
2000-12-05 |
Yu; Dingwei Tim |
Diaryl substituted thiazoles useful in the treatment of fungal infections
|
ATE301457T1
(de)
*
|
1995-06-12 |
2005-08-15 |
Searle & Co |
Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
|
US5700816A
(en)
*
|
1995-06-12 |
1997-12-23 |
Isakson; Peter C. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
|
US6342510B1
(en)
|
1995-06-12 |
2002-01-29 |
G. D. Searle & Co. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
|
US5968974A
(en)
|
1995-07-19 |
1999-10-19 |
Merck & Co., Inc. |
Method of treating colonic adenomas
|
US6593361B2
(en)
|
1995-07-19 |
2003-07-15 |
Merck & Co Inc |
Method of treating colonic adenomas
|
US5837719A
(en)
*
|
1995-08-10 |
1998-11-17 |
Merck & Co., Inc. |
2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
|
US5792778A
(en)
*
|
1995-08-10 |
1998-08-11 |
Merck & Co., Inc. |
2-substituted aryl pyrroles, compositions containing such compounds and methods of use
|
US5786515A
(en)
*
|
1995-09-15 |
1998-07-28 |
Merck & Co., Inc. |
Synthesis of α-chloro or fluoro ketones
|
CA2231550A1
(en)
*
|
1995-09-27 |
1997-04-03 |
Merck Frosst Canada Inc. |
Compositions for treating inflammation containing certain prostaglandins and a selective cyclooxygenase-2 inhibitor
|
US5717100A
(en)
*
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
US6083949A
(en)
*
|
1995-10-06 |
2000-07-04 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
US5981576A
(en)
*
|
1995-10-13 |
1999-11-09 |
Merck Frosst Canada, Inc. |
(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
|
UA57002C2
(uk)
*
|
1995-10-13 |
2003-06-16 |
Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. |
Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
|
US6020343A
(en)
*
|
1995-10-13 |
2000-02-01 |
Merck Frosst Canada, Inc. |
(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
|
CA2234633A1
(en)
*
|
1995-10-17 |
1997-04-24 |
G.D. Searle & Co. |
Method of detecting cyclooxygenase-2
|
ATE212343T1
(de)
*
|
1995-10-30 |
2002-02-15 |
Merck Frosst Canada Inc |
3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren
|
US6222048B1
(en)
*
|
1995-12-18 |
2001-04-24 |
Merck Frosst Canada & Co. |
Diaryl-2-(5H)-furanones as Cox-2 inhibitors
|
ATE236130T1
(de)
*
|
1996-01-26 |
2003-04-15 |
Searle & Co |
Heterocyclisch substituierte imidazole zur behandlung von entzündungen
|
US5789413A
(en)
*
|
1996-02-01 |
1998-08-04 |
Merck Frosst Canada, Inc. |
Alkylated styrenes as prodrugs to COX-2 inhibitors
|
ATE193526T1
(de)
*
|
1996-02-01 |
2000-06-15 |
Merck Frosst Canada Inc |
Alkylierte styrole als prodrugs zu cox-2- inhibitoren
|
US5733909A
(en)
*
|
1996-02-01 |
1998-03-31 |
Merck Frosst Canada, Inc. |
Diphenyl stilbenes as prodrugs to COX-2 inhibitors
|
SK102698A3
(en)
*
|
1996-02-01 |
1999-04-13 |
Merck Frosst Canada Inc |
Diphenyl stilbenes as prodrugs to cox-2 inhibitors
|
PT880362E
(pt)
*
|
1996-02-13 |
2005-10-31 |
Searle & Co |
Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4
|
DK0888127T3
(da)
|
1996-02-13 |
2002-04-08 |
Searle & Co |
Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer
|
PT880363E
(pt)
|
1996-02-13 |
2002-12-31 |
Searle & Co |
Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4
|
JP3995716B2
(ja)
*
|
1996-03-18 |
2007-10-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
縮合環含有カルボン酸誘導体
|
EP0889878B1
(de)
*
|
1996-03-29 |
2002-09-04 |
Merck Frosst Canada & Co. |
Bisarylcyclobutenderivate als cyclooxygenasehemmer
|
US5807873A
(en)
*
|
1996-04-04 |
1998-09-15 |
Laboratories Upsa |
Diarylmethylidenefuran derivatives and their uses in therapeutics
|
FR2747123B1
(fr)
*
|
1996-04-04 |
1998-06-26 |
Union Pharma Scient Appl |
Nouveaux derives diarylmethylidene tetrahydrofurane, leurs procedes de preparation, et leurs utilisations en therapeutique
|
US6180651B1
(en)
*
|
1996-04-04 |
2001-01-30 |
Bristol-Myers Squibb |
Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
|
US5908858A
(en)
*
|
1996-04-05 |
1999-06-01 |
Sankyo Company, Limited |
1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
|
EA003319B1
(ru)
|
1996-04-12 |
2003-04-24 |
Джи. Ди. Сирл Энд Ко. |
Производные замещенного бензолсульфонамида - пролекарства ингибиторов cox-2
|
US5922742A
(en)
*
|
1996-04-23 |
1999-07-13 |
Merck Frosst Canada |
Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
|
EP0900201A1
(de)
*
|
1996-04-23 |
1999-03-10 |
Merck Frosst Canada Inc. |
Pyridinyl-2-cyclopenten-1-one als selektive cyclooxygenase-2-hemmer
|
AU775030B2
(en)
*
|
1996-05-17 |
2004-07-15 |
Merck Frosst Company |
Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
|
CZ291463B6
(cs)
*
|
1996-05-17 |
2003-03-12 |
Merck And Co., Inc. |
Farmaceutický prostředek
|
CA2254121A1
(en)
*
|
1996-05-17 |
1997-11-27 |
Bruno Hancock |
Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
|
US6677364B2
(en)
|
1998-04-20 |
2004-01-13 |
G.D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
HRP970289A2
(en)
*
|
1996-05-31 |
1998-04-30 |
Merck & Co Inc |
Process for preparing phenyl heterocycles useful as cox-2 inhibitors
|
US5883267A
(en)
*
|
1996-05-31 |
1999-03-16 |
Merck & Co., Inc. |
Process for making phenyl heterocycles useful as cox-2 inhibitors
|
JP3418624B2
(ja)
*
|
1996-06-10 |
2003-06-23 |
メルク エンド カンパニー インコーポレーテッド |
サイトカイン阻害活性を有する置換イミダゾール類
|
GB9615867D0
(en)
*
|
1996-07-03 |
1996-09-11 |
Merck & Co Inc |
Process of preparing phenyl heterocycles useful as cox-2 inhibitors
|
US5677318A
(en)
*
|
1996-07-11 |
1997-10-14 |
Merck Frosst Canada, Inc. |
Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
|
IL128255A
(en)
*
|
1996-08-14 |
2004-06-20 |
Searle & Co |
Crystal form of –4 [–5 methyl –– 3 phenylisoxazole ––4yl] benzenesulfonamide
|
US6586458B1
(en)
*
|
1996-08-16 |
2003-07-01 |
Pozen Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US5939069A
(en)
*
|
1996-08-23 |
1999-08-17 |
University Of Florida |
Materials and methods for detection and treatment of immune system dysfunctions
|
FR2753449B1
(fr)
*
|
1996-09-13 |
1998-12-04 |
Union Pharma Scient Appl |
Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
|
WO1998016227A1
(en)
|
1996-10-15 |
1998-04-23 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
|
US5776954A
(en)
*
|
1996-10-30 |
1998-07-07 |
Merck & Co., Inc. |
Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
|
US5985930A
(en)
|
1996-11-21 |
1999-11-16 |
Pasinetti; Giulio M. |
Treatment of neurodegenerative conditions with nimesulide
|
PT946507E
(pt)
*
|
1996-12-10 |
2004-02-27 |
Searle & Co |
Compostos de pirrolilo substituidos para o tratamento da inflamacao
|
EP0863134A1
(de)
*
|
1997-03-07 |
1998-09-09 |
Merck Frosst Canada Inc. |
2-(3,5-difluorophenyl)-3-(4-methylsulfonylphenyl)-2-cyclopenten-1-on zur Verwendung als Inhibitor der Cyclooxygenase-2
|
CA2283399C
(en)
*
|
1997-03-14 |
2006-02-21 |
Merck Frosst Canada & Co. |
Pyridazinones as inhibitors of cyclooxygenase-2
|
US6071954A
(en)
*
|
1997-03-14 |
2000-06-06 |
Merk Frosst Canada, Inc. |
(methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
|
US6004960A
(en)
*
|
1997-03-14 |
1999-12-21 |
Merck Frosst Canada, Inc. |
Pyridazinones as inhibitors of cyclooxygenase-2
|
JP2001514668A
(ja)
*
|
1997-03-14 |
2001-09-11 |
メルク フロスト カナダ アンド カンパニー |
Cox−2阻害薬としての酸素連結部を有する(メチルスルホニル)フェニル−2−(5h)−フラノン類
|
TW492959B
(en)
*
|
1997-04-18 |
2002-07-01 |
Merck & Co Inc |
Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
|
US6127545A
(en)
*
|
1997-04-18 |
2000-10-03 |
Merck & Co., Inc. |
Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
|
US6130334A
(en)
*
|
1998-04-15 |
2000-10-10 |
Merck & Co., Inc. |
Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
|
US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
US6525053B1
(en)
|
1997-08-22 |
2003-02-25 |
Abbott Laboratories |
Prostaglandin endoperoxide H synthase biosynthesis inhibitors
|
US6307047B1
(en)
*
|
1997-08-22 |
2001-10-23 |
Abbott Laboratories |
Prostaglandin endoperoxide H synthase biosynthesis inhibitors
|
SK283922B6
(sk)
*
|
1997-09-05 |
2004-05-04 |
Glaxo Group Limited |
2,3-Diarylpyrazolo[1,5-b]pyridazínové zlúčeniny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
|
US6004950A
(en)
*
|
1997-09-12 |
1999-12-21 |
Merck Frosst Canada, Inc. |
2-aminopyridines as inhibitors of cyclooxygenase-2
|
WO1999014195A1
(en)
*
|
1997-09-12 |
1999-03-25 |
Merck Frosst Canada & Co. |
2-aminopyridines as inhibitors of cyclooxygenase-2
|
RS49982B
(sr)
*
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
US6034089A
(en)
*
|
1997-10-03 |
2000-03-07 |
Merck & Co., Inc. |
Aryl thiophene derivatives as PDE IV inhibitors
|
US6020339A
(en)
*
|
1997-10-03 |
2000-02-01 |
Merck & Co., Inc. |
Aryl furan derivatives as PDE IV inhibitors
|
FR2769311B1
(fr)
*
|
1997-10-07 |
1999-12-24 |
Union Pharma Scient Appl |
Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
|
US5972986A
(en)
*
|
1997-10-14 |
1999-10-26 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
|
US6080876A
(en)
*
|
1997-10-29 |
2000-06-27 |
Merck & Co., Inc. |
Process for making phenyl heterocycles useful as COX-2 inhibitors
|
WO1999023087A1
(en)
*
|
1997-10-30 |
1999-05-14 |
Merck Frosst Canada & Co. |
Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors
|
US6133292A
(en)
*
|
1997-10-30 |
2000-10-17 |
Merck Frosst Canada & Co. |
Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
|
CA2308639A1
(en)
*
|
1997-10-31 |
1999-05-14 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
|
US6025353A
(en)
*
|
1997-11-19 |
2000-02-15 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
|
EP1039914A4
(de)
*
|
1997-12-17 |
2007-06-27 |
Cornell Res Foundation Inc |
Cyclooxygenase-2 hemmung
|
US7041694B1
(en)
|
1997-12-17 |
2006-05-09 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
PT1685839E
(pt)
|
1997-12-22 |
2013-07-08 |
Euro Celtique Sa |
Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
|
NZ333399A
(en)
*
|
1997-12-24 |
2000-05-26 |
Sankyo Co |
Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
|
FR2775477B1
(fr)
*
|
1998-02-27 |
2000-05-19 |
Union Pharma Scient Appl |
Nouveaux derives diarylmethylene heterocycliques, leurs procedes de preparation et leurs utilisations en therapeutique
|
US6136804A
(en)
|
1998-03-13 |
2000-10-24 |
Merck & Co., Inc. |
Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
|
US6294558B1
(en)
|
1999-05-31 |
2001-09-25 |
Pfizer Inc. |
Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
|
US6727238B2
(en)
|
1998-06-11 |
2004-04-27 |
Pfizer Inc. |
Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
|
TNSN99111A1
(fr)
*
|
1998-06-11 |
2005-11-10 |
Pfizer |
Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
|
WO2000012093A1
(en)
*
|
1998-08-31 |
2000-03-09 |
Merck & Co., Inc. |
Method of treating neurodegenerative diseases
|
DE19842833B4
(de)
|
1998-09-18 |
2005-04-14 |
Merckle Gmbh |
2-Arylalkylthio-imidazole, 2-Arylalkenylthio-imidazole und 2-Arylalkinylthio-imidazole als Entzündungs-Hemmstoffe und Hemmstoffe der Cytokin-Freisetzung
|
WO2000024711A1
(en)
*
|
1998-10-27 |
2000-05-04 |
Merck & Co., Inc. |
Synthesis of methylthiophenyl hydroxyketones
|
DE69922688T2
(de)
*
|
1998-11-02 |
2005-12-01 |
Merck & Co. Inc. |
Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
|
BR9915011A
(pt)
|
1998-11-03 |
2001-08-07 |
Glaxo Group Ltd |
Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto
|
SA99191255B1
(ar)
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US6649645B1
(en)
*
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US6155267A
(en)
*
|
1998-12-31 |
2000-12-05 |
Medtronic, Inc. |
Implantable medical device monitoring method and system regarding same
|
CA2357525A1
(en)
*
|
1999-01-27 |
2000-08-03 |
Cornell Research Foundation, Inc. |
Treating cancers associated with overexpression of her-2/neu
|
EP1157025B1
(de)
|
1999-02-27 |
2004-03-10 |
Glaxo Group Limited |
Pyrazolopyridine
|
US20020002193A1
(en)
|
1999-03-25 |
2002-01-03 |
Yu Dingwei Tim |
Thiadiazole antifungal agents
|
KR20010094161A
(ko)
*
|
2000-04-04 |
2001-10-31 |
서경배 |
2,2-디메틸-4,5-디아릴-3(2h)퓨라논의 유도체 및 이를함유하는 선택적인 시클로옥시게네이즈-2 저해제로서약제학적 조성물
|
ATE256672T1
(de)
*
|
1999-04-14 |
2004-01-15 |
Pacific Corp |
4,5-diaryl-3(2h)-furanon derivate als cyclooxygenase-2 inhibitoren
|
CO5261541A1
(es)
*
|
1999-05-14 |
2003-03-31 |
Pfizer Prod Inc |
Terapia de combinacion para el tratamiento de la migrana
|
CO5190664A1
(es)
|
1999-06-30 |
2002-08-29 |
Pfizer Prod Inc |
Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
|
US6066667A
(en)
*
|
1999-08-17 |
2000-05-23 |
Ashbrook; Charles D. |
Substituted furanones, compositions and antiarthritic use
|
WO2001017996A1
(en)
*
|
1999-09-08 |
2001-03-15 |
Merck Frosst Canada & Co. |
1,2,3-thiadiazoles and their use as cox-2 inhibitors
|
EP1225901A2
(de)
*
|
1999-09-21 |
2002-07-31 |
Emory University |
Verwendungen und zusammensetzungen zur behandlung von blutplättchenverwandten krankheiten, mit anagrelide
|
ATE432269T1
(de)
|
1999-10-08 |
2009-06-15 |
Merial Sas |
Polymorphe form b von 3-(cyclopropylmethoxy)-4- 4-(methylsulfonyl)phe yl -5,5-dimethyl-5h-furan-2- on
|
EP1099695A1
(de)
*
|
1999-11-09 |
2001-05-16 |
Laboratoire Theramex S.A. |
5-Aryl-1H-1,2,4-triazolverbindungen als Cyclooxygenase-2 Inhibitoren und diese enthaltende pharmazeutische Zusammensetzungen
|
PT1104759E
(pt)
|
1999-12-03 |
2004-01-30 |
Pfizer Prod Inc |
Compostos heteroaril-fenil-pirazole como agentes anti-inflamatorios e analgesicos
|
US6506779B1
(en)
|
1999-12-03 |
2003-01-14 |
Pfizer Inc. |
Acetylene derivatives as anti-inflammatory/analgesic agents
|
JP2003517475A
(ja)
|
1999-12-03 |
2003-05-27 |
ファイザー・プロダクツ・インク |
抗炎症/鎮痛薬としてのヘテロシクロ−アルキルスルホニルピラゾール誘導体
|
ATE234299T1
(de)
|
1999-12-03 |
2003-03-15 |
Pfizer Prod Inc |
Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
NZ529933A
(en)
*
|
1999-12-08 |
2005-06-24 |
Pharmacia Corp |
Polymorphic crystalline forms of celecoxib
|
NZ513960A
(en)
*
|
1999-12-08 |
2004-02-27 |
Pharmacia Corp |
Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
|
GB9930358D0
(en)
|
1999-12-22 |
2000-02-09 |
Glaxo Group Ltd |
Process for the preparation of chemical compounds
|
CN100486573C
(zh)
*
|
1999-12-23 |
2009-05-13 |
硝化医药股份有限公司 |
硝基化的和亚硝基化的环加氧酶-2抑制剂、组合物及其用途
|
DE10001166A1
(de)
|
2000-01-13 |
2001-07-19 |
Merckle Gmbh |
Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
|
DE60138535D1
(de)
|
2000-02-04 |
2009-06-10 |
Children S Hospital Res Founda |
Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
|
ATE405264T1
(de)
|
2000-02-08 |
2008-09-15 |
Euro Celtique Sa |
Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten
|
CN100563656C
(zh)
|
2000-02-08 |
2009-12-02 |
欧罗赛铁克股份有限公司 |
抗破坏口服阿片样激动剂
|
WO2001081333A2
(en)
*
|
2000-04-25 |
2001-11-01 |
Pharmacia Corporation |
Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
|
ES2166710B1
(es)
*
|
2000-04-25 |
2004-10-16 |
J. URIACH & CIA, S.A. |
Nuevos compuestos heterociclicos con actividad antiinflamatoria.
|
MXPA03000161A
(es)
*
|
2000-05-22 |
2004-02-26 |
Reddy Research Foundation |
Compuestos novedosos los cuales tienen actividad antiinflamatoria, proceso para su preparacion y composiciones farmaceuticas que las contienen.
|
AU6837701A
(en)
*
|
2000-06-13 |
2001-12-24 |
American Home Prod |
Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
|
US6465509B2
(en)
|
2000-06-30 |
2002-10-15 |
Merck Frosst Canada & Co. |
Pyrones as inhibitors of cyclooxygenase-2
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
EP1299123A2
(de)
*
|
2000-07-13 |
2003-04-09 |
Pharmacia Corporation |
Verwendung von cox-2 hemmern zur behandlung und vorbeugung von cox-2-abhängigen augenkrankheiten
|
JP2004510705A
(ja)
*
|
2000-07-20 |
2004-04-08 |
ラウラス エイエス |
方法
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
PE20020506A1
(es)
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
WO2002017896A2
(en)
*
|
2000-08-29 |
2002-03-07 |
Peter Van Patten |
Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
|
GB0021494D0
(en)
*
|
2000-09-01 |
2000-10-18 |
Glaxo Group Ltd |
Chemical comkpounds
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
AU2001295038A1
(en)
*
|
2000-09-18 |
2002-03-26 |
Merck & Co., Inc. |
Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-V antagonist
|
DE10057366A1
(de)
*
|
2000-11-18 |
2002-05-23 |
Mahle Gmbh |
Verfahren zur gießtechnischen Herstellung eines Kolbens mit einem gekühlten Ringträger
|
EP1377573B1
(de)
|
2000-12-15 |
2005-07-27 |
Glaxo Group Limited |
Pyrazolopyridinderivate
|
AU2002239344A1
(en)
|
2000-12-15 |
2002-06-24 |
Glaxo Group Limited |
Pyrazolopyridines
|
ATE338544T1
(de)
|
2000-12-21 |
2006-09-15 |
Nitromed Inc |
Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
AUPR283801A0
(en)
*
|
2001-02-01 |
2001-03-01 |
Australian National University, The |
Chemical compounds and methods
|
US20030008870A1
(en)
*
|
2001-02-02 |
2003-01-09 |
Joel Krasnow |
Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dysmenorrhea
|
DE10107683A1
(de)
|
2001-02-19 |
2002-08-29 |
Merckle Gmbh Chem Pharm Fabrik |
2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
|
ATE274515T1
(de)
|
2001-03-08 |
2004-09-15 |
Smithkline Beecham Corp |
Pyrazolopyridinderivate
|
US7034030B2
(en)
|
2001-03-30 |
2006-04-25 |
Smithkline Beecham Corporation |
Pyralopyridines, process for their preparation and use as therapeutic compounds
|
PE20021017A1
(es)
|
2001-04-03 |
2002-11-24 |
Pharmacia Corp |
Composicion parenteral reconstituible
|
US7141569B2
(en)
|
2001-04-10 |
2006-11-28 |
Smithkline Beecham Corporation |
Antiviral pyrazolopyridine compounds
|
US20030105144A1
(en)
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
US6673818B2
(en)
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
US6756498B2
(en)
|
2001-04-27 |
2004-06-29 |
Smithkline Beecham Corporation |
Process for the preparation of chemical compounds
|
DE60204452T2
(de)
|
2001-04-27 |
2005-12-15 |
Smithkline Beecham Corp. |
Pyrazolo[1,5a]Pyridinderivate
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
CA2445502A1
(en)
*
|
2001-05-04 |
2002-11-14 |
Merck & Co., Inc. |
Method and compositions for treating migraines
|
JP4522652B2
(ja)
|
2001-05-11 |
2010-08-11 |
エンドー ファーマシューティカルズ, インコーポレイティド |
乱用防止制御放出オピオイド投薬形態
|
GB0112810D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
GB0112802D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
IL159100A0
(en)
*
|
2001-05-31 |
2004-05-12 |
Pharmacia Corp |
Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor and a monohydric alcohol
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
EP1401836B1
(de)
|
2001-06-21 |
2006-08-23 |
SmithKline Beecham Corporation |
Imidazo¬1,2-a|pyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
|
ES2241964T3
(es)
|
2001-07-05 |
2005-11-01 |
Pfizer Products Inc. |
Heterocicloalquilsulfufonilpirazoles como agentes antiinflamatorios/abnalgesicos.
|
DE60230632D1
(de)
|
2001-07-18 |
2009-02-12 |
Euro Celtique Sa |
Pharmazeutische kombinationen von oxycodon und naloxon
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
KR20040029405A
(ko)
|
2001-08-06 |
2004-04-06 |
유로-셀티크 소시에떼 아노뉨 |
방출성 및 격리된 길항제와 오피오이드 효능제의 제제
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
AU2002324624A1
(en)
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
GB0119477D0
(en)
*
|
2001-08-09 |
2001-10-03 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
WO2003018575A1
(en)
*
|
2001-08-24 |
2003-03-06 |
Wyeth Holdings Corporation |
5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
AP2004002999A0
(en)
*
|
2001-09-26 |
2004-03-31 |
Pharmacia Corp |
Organoleptically acceptable intraorally disintegrating compositions
|
GT200200183A
(es)
|
2001-09-28 |
2003-05-23 |
|
Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
|
ATE326466T1
(de)
|
2001-10-05 |
2006-06-15 |
Smithkline Beecham Corp |
Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
|
KR100810468B1
(ko)
|
2001-10-10 |
2008-03-07 |
씨제이제일제당 (주) |
사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1h-인돌 유도체
|
KR100824233B1
(ko)
|
2001-10-10 |
2008-04-24 |
씨제이제일제당 (주) |
사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1h-나프탈렌 유도체
|
WO2003037336A1
(en)
|
2001-11-02 |
2003-05-08 |
Pfizer Products Inc. |
1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
|
DE60231439D1
(de)
|
2001-12-06 |
2009-04-16 |
Merck & Co Inc |
Mitotische kinesinhemmer
|
FR2833164B1
(fr)
*
|
2001-12-07 |
2004-07-16 |
Oreal |
Compositions cosmetiques antisolaires a base d'un melange synergique de filtres et utilisations
|
ES2292839T3
(es)
|
2001-12-11 |
2008-03-16 |
Smithkline Beecham Corporation |
Derivados de pirazolo-piridina como agentes contra el herpes.
|
US20040082940A1
(en)
*
|
2002-10-22 |
2004-04-29 |
Michael Black |
Dermatological apparatus and method
|
DE10162120A1
(de)
*
|
2001-12-12 |
2003-06-18 |
Berolina Drug Dev Ab Svedala |
Deuterierte substituierte Dihydrofuranone sowie diese Verbindungen enthaltende Arzneimittel
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
US20030212138A1
(en)
*
|
2002-01-14 |
2003-11-13 |
Pharmacia Corporation |
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
|
US6667330B2
(en)
|
2002-01-31 |
2003-12-23 |
Galileo Pharmaceuticals, Inc. |
Furanone derivatives
|
US7985771B2
(en)
*
|
2002-01-31 |
2011-07-26 |
Monsanto Technology Llc |
Furanone derivatives
|
LT2425825T
(lt)
|
2002-04-05 |
2017-02-27 |
Euro-Celtique S.A. |
Farmacinis preparatas, turintis oksikodono ir naloksono
|
RU2004132721A
(ru)
*
|
2002-04-08 |
2005-06-27 |
Глэксо Груп Лимитед (GB) |
(2-алкокси)фенил)циклопент-1-енил)ароматическая карбо- и гетероциклическая карбоновая кислота и ее производные
|
IL164163A0
(en)
*
|
2002-04-09 |
2005-12-18 |
Pharmacia Corp |
Process for preparing a finely self-emulsifiable pharmaceutical composition
|
US7329401B2
(en)
|
2002-04-15 |
2008-02-12 |
The Regents Of The University Of California |
Cyclooxygenase-2 selective agents useful as imaging probes and related methods
|
EP1495132B1
(de)
|
2002-04-17 |
2013-08-28 |
The Cleveland Clinic Foundation |
Systemischer marker zur überwachung von antiinflammatorischen und antioxidativen wirkungen von therapeutika
|
BR0309412A
(pt)
*
|
2002-04-22 |
2005-02-01 |
Pfizer Prod Inc |
Indol-2-onas como inibidores seletivos da ciclooxigenase-2
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
EP3425059A1
(de)
|
2002-05-09 |
2019-01-09 |
The Brigham and Women's Hospital, Inc. |
1l1rl-1 als ein marker kardiovaskulärer krankheiten
|
WO2003095623A2
(en)
*
|
2002-05-10 |
2003-11-20 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
|
KR100804827B1
(ko)
*
|
2002-05-17 |
2008-02-20 |
씨제이제일제당 (주) |
티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
|
US20030225054A1
(en)
*
|
2002-06-03 |
2003-12-04 |
Jingwu Duan |
Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
|
KR100478467B1
(ko)
|
2002-06-24 |
2005-03-23 |
씨제이 주식회사 |
피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물
|
KR100465455B1
(ko)
*
|
2002-06-24 |
2005-01-13 |
씨제이 주식회사 |
2-티옥소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
US7087630B2
(en)
*
|
2002-06-27 |
2006-08-08 |
Nitromed, Inc. |
Cyclooxygenase 2 selective inhibitors, compositions and methods of use
|
AU2003279622A1
(en)
*
|
2002-06-28 |
2004-01-19 |
Nitromed, Inc. |
Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
|
AU2003248759A1
(en)
*
|
2002-07-02 |
2004-01-23 |
Pharmacia Corporation |
Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event
|
KR100467668B1
(ko)
|
2002-08-07 |
2005-01-24 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
ES2263058T3
(es)
*
|
2002-08-19 |
2006-12-01 |
Glaxo Group Limited |
Derivados de pirimidina como inhibidores selectivos de cox-2.
|
DE10238045A1
(de)
|
2002-08-20 |
2004-03-04 |
Merckle Gmbh Chem.-Pharm. Fabrik |
2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
GB0221443D0
(en)
|
2002-09-16 |
2002-10-23 |
Glaxo Group Ltd |
Pyridine derivates
|
CN1703200B
(zh)
|
2002-09-20 |
2012-02-29 |
奥尔制药公司 |
隔离亚单元和相关组合物及方法
|
US8303511B2
(en)
*
|
2002-09-26 |
2012-11-06 |
Pacesetter, Inc. |
Implantable pressure transducer system optimized for reduced thrombosis effect
|
EP1546148A1
(de)
|
2002-10-03 |
2005-06-29 |
SmithKline Beecham Corporation |
Auf pyrazolopyridinderivaten basierende therapeutische verbindungen
|
ES2357948T3
(es)
*
|
2002-10-08 |
2011-05-04 |
Rinat Neuroscience Corp. |
Procedimientos para tratar dolor postquirúrgico mediante la administración de un anticuerpo frente al factor de crecimiento nervioso y composiciones que contienen el mismo.
|
WO2005000194A2
(en)
|
2002-10-08 |
2005-01-06 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
KR100484525B1
(ko)
*
|
2002-10-15 |
2005-04-20 |
씨제이 주식회사 |
이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
WO2004041162A2
(en)
*
|
2002-10-30 |
2004-05-21 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
GB0225548D0
(en)
*
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Compounds
|
WO2004041803A1
(en)
*
|
2002-11-05 |
2004-05-21 |
Merck Frosst Canada & Co. |
Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
|
WO2004043358A2
(en)
*
|
2002-11-08 |
2004-05-27 |
Bristol-Myers Squibb Company |
Formulations of low solubility bioactive agents and processes for making the same
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
KR100470075B1
(ko)
|
2002-11-21 |
2005-02-05 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
GB0227443D0
(en)
*
|
2002-11-25 |
2002-12-31 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
KR100491317B1
(ko)
|
2002-11-26 |
2005-05-24 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
KR100470076B1
(ko)
|
2002-11-27 |
2005-02-05 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
NZ567457A
(en)
|
2002-12-13 |
2009-08-28 |
Warner Lambert Co |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
BR0317539A
(pt)
*
|
2002-12-19 |
2005-11-22 |
Pharmacia Corp |
Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
|
US20040171664A1
(en)
*
|
2002-12-20 |
2004-09-02 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
SI2263692T1
(sl)
*
|
2002-12-24 |
2020-10-30 |
Rinat Neuroscience Corp. |
Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
ES2215474B1
(es)
*
|
2002-12-24 |
2005-12-16 |
J. URIACH & CIA S.A. |
Nuevos derivados de fosforamida.
|
WO2004060355A1
(en)
*
|
2002-12-26 |
2004-07-22 |
Pozen Inc. |
Multilayer Dosage Forms Containing NSAIDs and Triptans
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20070265606A1
(en)
*
|
2003-02-14 |
2007-11-15 |
Reliant Technologies, Inc. |
Method and Apparatus for Fractional Light-based Treatment of Obstructive Sleep Apnea
|
BRPI0407375A
(pt)
|
2003-02-19 |
2006-02-07 |
Rinat Neuroscience Corp |
Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
|
US20040214753A1
(en)
*
|
2003-03-20 |
2004-10-28 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
CA2519125A1
(en)
*
|
2003-03-20 |
2004-09-30 |
Pharmacia Corporation |
Dispersible formulation of an anti-inflammatory agent
|
US20050004098A1
(en)
*
|
2003-03-20 |
2005-01-06 |
Britten Nancy Jean |
Dispersible formulation of an anti-inflammatory agent
|
US20050009931A1
(en)
*
|
2003-03-20 |
2005-01-13 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
WO2004093814A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
|
US20040229803A1
(en)
*
|
2003-04-22 |
2004-11-18 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
|
WO2004093813A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
|
US20050159403A1
(en)
*
|
2003-04-22 |
2005-07-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
|
US20050107387A1
(en)
*
|
2003-05-13 |
2005-05-19 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
WO2004105699A2
(en)
*
|
2003-05-28 |
2004-12-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
RS20050890A
(en)
|
2003-05-30 |
2007-12-31 |
Ranbaxy Laboratories Limited, |
Substituted pyrrole derivatives
|
CN1309717C
(zh)
*
|
2003-06-03 |
2007-04-11 |
李小虎 |
4-芳基-5h-噻吩-2-酮衍生物、其制法和用途
|
KR20060015641A
(ko)
*
|
2003-06-06 |
2006-02-17 |
글락소 그룹 리미티드 |
트립탄 및 nsaid를 포함하는 조성물
|
WO2005000238A2
(en)
*
|
2003-06-20 |
2005-01-06 |
Merck & Co., Inc. |
Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis
|
US20050065154A1
(en)
*
|
2003-06-24 |
2005-03-24 |
Pharmacia Corporation |
Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents
|
US20050101597A1
(en)
*
|
2003-07-10 |
2005-05-12 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
|
US20050014729A1
(en)
*
|
2003-07-16 |
2005-01-20 |
Pharmacia Corporation |
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
|
WO2005009354A2
(en)
*
|
2003-07-17 |
2005-02-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
|
JP2007502831A
(ja)
*
|
2003-08-20 |
2007-02-15 |
ニトロメッド インコーポレーティッド |
ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
JP2007504135A
(ja)
*
|
2003-08-28 |
2007-03-01 |
ニトロメッド インコーポレーティッド |
ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
|
CA2536622C
(en)
|
2003-08-29 |
2014-02-11 |
The Brigham And Women's Hospital, Inc. |
Inhibitors of cellular necrosis
|
WO2005023189A2
(en)
*
|
2003-09-03 |
2005-03-17 |
Pharmacia Corporation |
Method of cox-2 selective inhibitor and nitric oxide-donating agent
|
US20050131028A1
(en)
*
|
2003-09-11 |
2005-06-16 |
Pharmacia Corporation |
Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
|
EP1663229B1
(de)
|
2003-09-25 |
2010-04-14 |
Euro-Celtique S.A. |
Pharmazeutische kombinationen von hydrocodon und naltrexon
|
GB0323581D0
(en)
*
|
2003-10-08 |
2003-11-12 |
Glaxo Group Ltd |
Novel compounds
|
GB0323585D0
(en)
*
|
2003-10-08 |
2003-11-12 |
Glaxo Group Ltd |
Compounds
|
GB0323584D0
(en)
*
|
2003-10-08 |
2003-11-12 |
Glaxo Group Ltd |
Compounds
|
FR2860792B1
(fr)
*
|
2003-10-10 |
2006-02-24 |
Sanofi Synthelabo |
Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
|
WO2005044227A1
(en)
*
|
2003-11-05 |
2005-05-19 |
Glenmark Pharmaceuticals Limited |
Topical pharmaceutical compositions
|
US20050100594A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Nilendu Sen |
Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
|
ATE473967T1
(de)
*
|
2003-11-26 |
2010-07-15 |
Pfizer Prod Inc |
Aminopyrazolderivate als gsk-3-inhibitoren
|
EP2306192B1
(de)
|
2003-12-05 |
2015-10-14 |
The Cleveland Clinic Foundation |
Risikomarker für eine Herzkreislaufkrankheit
|
US7067159B2
(en)
*
|
2003-12-05 |
2006-06-27 |
New Chapter, Inc. |
Methods for treating prostate cancer with herbal compositions
|
US7070816B2
(en)
*
|
2003-12-05 |
2006-07-04 |
New Chapter, Inc. |
Methods for treating prostatic intraepithelial neoplasia with herbal compositions
|
JP2007518788A
(ja)
|
2004-01-22 |
2007-07-12 |
ファイザー・インク |
バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
|
US20090131342A1
(en)
*
|
2004-01-22 |
2009-05-21 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
WO2005081960A2
(en)
*
|
2004-02-25 |
2005-09-09 |
Wyeth |
Inhibitors of protein tyrosine phosphatase 1b
|
AR047894A1
(es)
*
|
2004-02-25 |
2006-03-01 |
Wyeth Corp |
Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b
|
HUE037549T2
(hu)
|
2004-04-07 |
2018-09-28 |
Rinat Neuroscience Corp |
Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával
|
MXPA06012510A
(es)
*
|
2004-04-28 |
2006-12-15 |
Pfizer |
Derivados de 3-heterociclil-4-fenil-triazol como inhibidores del receptor de vasopresina via.
|
GB0410121D0
(en)
*
|
2004-05-06 |
2004-06-09 |
Glaxo Group Ltd |
Compounds
|
US7507823B2
(en)
*
|
2004-05-06 |
2009-03-24 |
Bristol-Myers Squibb Company |
Process of making aripiprazole particles
|
WO2005120584A2
(en)
*
|
2004-06-03 |
2005-12-22 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled arylsulfonyl compounds and uses thereof
|
EP1604666A1
(de)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
|
ES2653568T3
(es)
|
2004-06-12 |
2018-02-07 |
Collegium Pharmaceutical, Inc. |
Formulaciones de fármacos para la prevención del abuso
|
JP2008505085A
(ja)
|
2004-07-01 |
2008-02-21 |
メルク エンド カムパニー インコーポレーテッド |
有糸分裂キネシン阻害剤
|
ES2257929B1
(es)
*
|
2004-07-16 |
2007-05-01 |
Laboratorios Del Dr. Esteve, S.A. |
Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
|
JP2008506768A
(ja)
*
|
2004-07-22 |
2008-03-06 |
ファルマシア コーポレーション |
Cox−2選択的阻害剤とltb4受容体アンタゴニストを組み合わせて用いる炎症および疼痛を治療するための組成物
|
WO2006137839A2
(en)
|
2004-08-24 |
2006-12-28 |
Merck & Co., Inc. |
Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
|
US7622142B2
(en)
*
|
2004-09-14 |
2009-11-24 |
New Chapter Inc. |
Methods for treating glioblastoma with herbal compositions
|
US20060064142A1
(en)
*
|
2004-09-17 |
2006-03-23 |
Cardiac Pacemakers, Inc. |
Systems and methods for deriving relative physiologic measurements using an implanted sensor device
|
US8067464B2
(en)
|
2004-10-04 |
2011-11-29 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
EP1809759B1
(de)
|
2004-10-06 |
2013-09-11 |
The Brigham And Women's Hospital, Inc. |
Relevanz erzielter niveaus von markern für systemische entzündung nach behandlung
|
CA2576279A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
|
US20080275093A1
(en)
*
|
2004-11-15 |
2008-11-06 |
Nitromed, Inc. |
Diuretic Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
|
JP2008525363A
(ja)
|
2004-12-23 |
2008-07-17 |
グラクソ グループ リミテッド |
プロスタグランジン媒介疾患治療のためのピリジン化合物
|
NZ555693A
(en)
|
2004-12-27 |
2010-10-29 |
Eisai R&D Man Co Ltd |
Matrix type sustained-release preparation containing donepezil
|
US20080306041A1
(en)
*
|
2005-01-21 |
2008-12-11 |
Garvey David S |
Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
|
CA2596426A1
(en)
*
|
2005-01-31 |
2006-08-10 |
Mylan Laboratories, Inc. |
Pharmaceutical composition comprising hydroxylated nebivolol
|
WO2007086884A2
(en)
*
|
2005-02-16 |
2007-08-02 |
Nitromed, Inc. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
US7521435B2
(en)
*
|
2005-02-18 |
2009-04-21 |
Pharma Diagnostics, N.V. |
Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
|
EP1702558A1
(de)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Verfahren und Vorrichtung zur Darmtätigkeitserfassung
|
CA2597463A1
(en)
*
|
2005-02-28 |
2006-09-08 |
Nitromed, Inc. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
EP1861093A2
(de)
*
|
2005-03-09 |
2007-12-05 |
Nitromed, Inc. |
Organische stickoxide verbessernde salze von angiotensin-ii-antagonisten , zusammensetzungen und verwendungsverfahren
|
WO2006110918A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Ambit Biosciences Corporation |
Pyrrole compounds and uses thereof
|
WO2006118265A1
(ja)
*
|
2005-04-28 |
2006-11-09 |
Eisai R & D Management Co., Ltd. |
抗痴呆薬を含有する組成物
|
CA2607913C
(en)
*
|
2005-05-05 |
2014-03-18 |
Cook Biotech Incorporated |
Implantable materials and methods for inhibiting tissue adhesion formation
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
US20080234252A1
(en)
*
|
2005-05-18 |
2008-09-25 |
Pfizer Inc |
Compounds Useful in Therapy
|
US20090048219A1
(en)
*
|
2005-05-23 |
2009-02-19 |
Nitromed Inc. |
Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
|
SG162734A1
(en)
|
2005-05-31 |
2010-07-29 |
Mylan Lab Inc |
Compositions comprising nebivolol
|
WO2007016677A2
(en)
|
2005-08-02 |
2007-02-08 |
Nitromed, Inc. |
Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
|
PE20070427A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
|
EP1942909A4
(de)
*
|
2005-10-04 |
2010-01-06 |
Nitromed Inc |
Verfahren zur behandlung von atemwegserkrankungen
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
JP2009514851A
(ja)
|
2005-11-08 |
2009-04-09 |
ランバクシー ラボラトリーズ リミテッド |
(3r,5r)−7−[2−(4−フルオロフェニル)−5−イソプロピル−3−フェニル−4−[(4−ヒドロキシメチルフェニルアミノ)カルボニル]−ピロール−1−イル]−3,5−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
|
EP1954685A4
(de)
*
|
2005-11-16 |
2009-11-11 |
Nitromed Inc |
Furoxanverbindungen, zusammensetzungen und anwendungsverfahren
|
TW200735866A
(en)
|
2005-11-18 |
2007-10-01 |
Synta Pharmaceuticals Corp |
Compounds for the treatment of proliferative disorders
|
WO2007075541A2
(en)
*
|
2005-12-20 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
EP1971340A2
(de)
*
|
2005-12-22 |
2008-09-24 |
Nitromed, Inc. |
Stickoxid-verstärkende pyruvat-verbindungen, zusammensetzungen und anwendungsverfahren
|
US20090062302A1
(en)
|
2006-01-24 |
2009-03-05 |
Buser-Doepner Carolyn A |
Jak2 Tyrosine Kinase Inhibition
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
PT3279663T
(pt)
|
2006-03-15 |
2021-09-24 |
Brigham & Womens Hospital Inc |
Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
|
AU2007243765A1
(en)
|
2006-03-29 |
2007-11-08 |
Nicox S.A. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
US7553854B2
(en)
|
2006-04-19 |
2009-06-30 |
Novartis Vaccines And Diagnostics, Inc. |
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
|
WO2007146229A2
(en)
|
2006-06-07 |
2007-12-21 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
MX2008016372A
(es)
|
2006-06-19 |
2009-05-28 |
Alpharma Inc |
Composiciones farmaceuticas.
|
US8128460B2
(en)
*
|
2006-09-14 |
2012-03-06 |
The Material Works, Ltd. |
Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
|
EP2946778A1
(de)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Behandlungsverfahren mit verwendung von fettsäuresyntheseinhibitoren
|
US20080208179A1
(en)
*
|
2006-10-26 |
2008-08-28 |
Reliant Technologies, Inc. |
Methods of increasing skin permeability by treatment with electromagnetic radiation
|
US8513329B2
(en)
|
2006-10-31 |
2013-08-20 |
Bio-Tec Environmental, Llc |
Chemical additives to make polymeric materials biodegradable
|
JP5280368B2
(ja)
|
2006-10-31 |
2013-09-04 |
バイオ−テック エンバイロメンタル,エルエルシー |
高分子材料を生分解性にする化学添加剤
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
UA94979C2
(uk)
|
2006-12-22 |
2011-06-25 |
Рекордати Айеленд Лимитед |
КОМБІНОВАНА ТЕРАПІЯ ПОРУШЕНЬ НИЖНІХ СЕЧОВИВІДНИХ ШЛЯХІВ ЛІГАНДАМИ α2δ І НПЗП
|
EA016079B1
(ru)
|
2007-01-10 |
2012-01-30 |
Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа |
Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
|
CN101626787A
(zh)
*
|
2007-01-19 |
2010-01-13 |
马林克罗特公司 |
诊断的和治疗的环氧合酶-2结合配体
|
BRPI0808523A2
(pt)
|
2007-03-01 |
2014-08-19 |
Novartis Vaccines & Diagnostic |
Inibidores de pim cinase e métodos de seu uso
|
GB0704407D0
(en)
|
2007-03-07 |
2007-04-18 |
Glaxo Group Ltd |
Compounds
|
TW200849035A
(en)
|
2007-04-18 |
2008-12-16 |
Tethys Bioscience Inc |
Diabetes-related biomarkers and methods of use thereof
|
JP5378362B2
(ja)
|
2007-05-21 |
2013-12-25 |
ノバルティス アーゲー |
Csf−1r阻害剤、組成物および使用方法
|
WO2009002495A1
(en)
|
2007-06-27 |
2008-12-31 |
Merck & Co., Inc. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
WO2009009778A1
(en)
|
2007-07-12 |
2009-01-15 |
Tragara Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
|
US7943658B2
(en)
*
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
CA2699157A1
(en)
|
2007-09-10 |
2009-03-19 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
KR20100126467A
(ko)
|
2008-03-03 |
2010-12-01 |
타이거 파마테크 |
티로신 키나아제 억제제
|
GB2460915B
(en)
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
RU2472791C2
(ru)
|
2008-08-27 |
2013-01-20 |
КалсиМедика Инк. |
Соединения, модулирующие внутриклеточный кальций
|
EP2177215A1
(de)
|
2008-10-17 |
2010-04-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Co-Kristalle von Tramadol und NSARs
|
CN101429181A
(zh)
*
|
2008-12-18 |
2009-05-13 |
毛近隆 |
对羟基苯丙烯酸衍生物及其应用
|
WO2010071865A1
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
US20100160351A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
BRPI1006186A2
(pt)
|
2009-03-10 |
2016-08-23 |
Euro Celtique Sa |
composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
|
WO2011012622A1
(en)
|
2009-07-30 |
2011-02-03 |
Glaxo Group Limited |
Benzoxazinone derivatives for the treatment of glytl mediated disorders
|
WO2011023753A1
(en)
|
2009-08-27 |
2011-03-03 |
Glaxo Group Limited |
Benzoxazine derivatives as glycine transport inhibitors
|
WO2011032175A1
(en)
|
2009-09-14 |
2011-03-17 |
Nuon Therapeutics, Inc. |
Combination formulations of tranilast and allopurinol and methods related thereto
|
BR112012008849A2
(pt)
|
2009-10-14 |
2015-09-22 |
Schering Corp |
composto, composição farmacêutica, e, uso de um composto
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US8586624B2
(en)
|
2009-12-16 |
2013-11-19 |
N30 Pharmaceuticals, Inc. |
Thiophene inhibitors of S-nitrosoglutathione reductase
|
GB201000685D0
(en)
|
2010-01-15 |
2010-03-03 |
Glaxo Group Ltd |
Novel compounds
|
WO2011094730A2
(en)
|
2010-02-01 |
2011-08-04 |
The Hospital For Sick Children |
Remote ischemic conditioning for treatment and reventon of restenosis
|
AU2011234189B2
(en)
|
2010-03-31 |
2015-12-03 |
The Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
JP2013525448A
(ja)
|
2010-04-27 |
2013-06-20 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
JP6112486B2
(ja)
|
2010-04-27 |
2017-04-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
GB201007791D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel compounds
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
EP2584903B1
(de)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Neue heterozyklische verbindungen als erk-hemmer
|
JP5815029B2
(ja)
|
2010-07-09 |
2015-11-17 |
クオンベルゲンセ プハルマセウトイカルス リミテッド |
カルシウムチャネル遮断薬としてのテトラゾール化合物
|
EP3330377A1
(de)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
|
US9029341B2
(en)
|
2010-08-17 |
2015-05-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
LT3333188T
(lt)
|
2010-08-19 |
2022-06-10 |
Zoetis Belgium S.A. |
Anti-ngf antikūnai ir jų panaudojimas
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012027710A2
(en)
|
2010-08-27 |
2012-03-01 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
KR101572336B1
(ko)
|
2010-12-22 |
2015-11-26 |
퍼듀 퍼머 엘피 |
케이싱된 탬퍼 저항성 제어 방출 투여 형태
|
AU2011346758C1
(en)
|
2010-12-23 |
2015-09-03 |
Purdue Pharma L.P. |
Tamper resistant solid oral dosage forms
|
JP6058556B2
(ja)
|
2011-01-19 |
2017-01-11 |
クオンベルゲンセ プハルマセウトイカルス リミテッド |
CaV2.2カルシウムチャンネルブロッカーとしてのピペラジン誘導体
|
JP2014514321A
(ja)
|
2011-04-21 |
2014-06-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
インスリン様増殖因子1受容体阻害剤
|
CN107602700B
(zh)
|
2011-05-20 |
2021-12-17 |
H.伦德贝克公司 |
抗cgrp组合物及其用途
|
EP2770987B1
(de)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Neue verbindungen als erk-hemmer
|
EP2773207B1
(de)
|
2011-10-31 |
2018-03-07 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinone als interleukinrezeptor-assoziierte kinaseinhibitoren
|
GB201122113D0
(en)
|
2011-12-22 |
2012-02-01 |
Convergence Pharmaceuticals |
Novel compounds
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
JP6377054B2
(ja)
|
2012-05-11 |
2018-08-22 |
リセット セラピューティークス, インコーポレイテッド |
クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
|
ES2894852T3
(es)
|
2012-06-06 |
2022-02-16 |
Zoetis Services Llc |
Anticuerpos anti-NGF caninizados y métodos de los mismos
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
AU2013352568B2
(en)
|
2012-11-28 |
2019-09-19 |
Merck Sharp & Dohme Llc |
Compositions and methods for treating cancer
|
CN105073746B
(zh)
|
2012-12-20 |
2017-03-22 |
默沙东公司 |
作为hdm2抑制剂的取代的咪唑并吡啶
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
WO2014123899A1
(en)
|
2013-02-05 |
2014-08-14 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
US9725452B2
(en)
|
2013-03-15 |
2017-08-08 |
Presidents And Fellows Of Harvard College |
Substituted indoles and pyrroles as RIP kinase inhibitors
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
TWI634114B
(zh)
*
|
2013-05-08 |
2018-09-01 |
永恒生物科技公司 |
作為激酶抑制劑之呋喃酮化合物
|
EP3019171B1
(de)
|
2013-07-11 |
2018-09-05 |
Merck Sharp & Dohme Corp. |
Substituierte amidopyrazolhemmer von interleukinrezeptor-assoziierten kinasen (irak-4)
|
EP3024461B1
(de)
|
2013-07-23 |
2020-05-13 |
Euro-Celtique S.A. |
Kombination aus oxycodon und naloxon für die verwendung bei der behandlung von schmerzen bei patienten mit schmerzen und einer krankheit, die zur intestinaldysbiose und/oder erhöhung der gefahr bakterieller translokation führt
|
EP3041938A1
(de)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Kreisförmige polynukleotide
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US10413520B2
(en)
|
2014-01-29 |
2019-09-17 |
Crystalgenomics, Inc. |
Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability
|
KR101446601B1
(ko)
*
|
2014-01-29 |
2014-10-07 |
크리스탈지노믹스(주) |
5-(4-(아미노설포닐)페닐)-2,2-디메틸-4-(3-플루오로페닐)-3(2h)-퓨라논을 포함하는 약학적 조성물 및 캡슐 제형
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
GB201417499D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417500D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417497D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
RU2563876C1
(ru)
*
|
2014-11-11 |
2015-09-27 |
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный университет" (СПбГУ) |
Способ получения 2,2-диалкил-4,5-диарилфуран-3(2н)-онов
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
EP3268003B1
(de)
|
2015-03-12 |
2020-07-29 |
Merck Sharp & Dohme Corp. |
Thienopyrazininhibitoren der irak4-aktivität
|
WO2016144846A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
WO2016177776A1
(en)
|
2015-05-04 |
2016-11-10 |
Academisch Medisch Centrum |
Biomarkers for the detection of aspirin insensitivity
|
SG11201808630WA
(en)
|
2016-04-15 |
2018-10-30 |
Alder Biopharmaceuticals Inc |
Humanized anti-pacap antibodies and uses thereof
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
EP3487495A1
(de)
|
2016-07-21 |
2019-05-29 |
Unilever PLC |
Lactame zur verwendung bei der behandlung von hautkrankheiten
|
BR112019001134A2
(pt)
|
2016-07-21 |
2019-04-30 |
Unilever N.V. |
uso de lactama e composição farmacêutica
|
WO2018015280A1
(en)
|
2016-07-21 |
2018-01-25 |
Unilever Plc |
4-(4-chlorophenyl)-5-methylene-pyrrol-2-one and 5-methylene-4-(p-tolyl)pyrrol-2-one for use in the treatment of gram negative bacterial infections
|
EP3706742B1
(de)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
AU2019234213A1
(en)
|
2018-03-12 |
2020-09-03 |
Zoetis Services Llc |
Anti-NGF antibodies and methods thereof
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833668A4
(de)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
Prmt5-inhibitoren
|
US20220031631A1
(en)
|
2018-09-19 |
2022-02-03 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
JP2022501359A
(ja)
|
2018-09-19 |
2022-01-06 |
モデルナティーエックス, インコーポレイテッド |
Peg脂質及びそれらの使用
|
JP7291220B2
(ja)
*
|
2018-11-21 |
2023-06-14 |
トレモ― ファーマシューティカルズ,インコーポレーテッド |
ロフェコキシブの精製形態、製造方法および使用
|
CN110452198B
(zh)
*
|
2019-09-03 |
2021-03-26 |
山东鲁抗舍里乐药业有限公司 |
一种非罗考昔的制备方法
|
CN110452199B
(zh)
*
|
2019-09-03 |
2021-03-30 |
山东鲁抗舍里乐药业有限公司 |
一种非罗考昔的制备方法
|
US10945992B1
(en)
|
2019-11-13 |
2021-03-16 |
Tremeau Pharmaceuticals, Inc. |
Dosage forms of rofecoxib and related methods
|
CA3160153A1
(en)
|
2019-12-17 |
2021-06-24 |
Michelle Machacek |
Prmt5 inhibitors
|
CN114014824B
(zh)
*
|
2020-12-09 |
2023-06-13 |
上海科技大学 |
一种杂环化合物的应用
|
US20240199571A1
(en)
*
|
2021-03-11 |
2024-06-20 |
Medshine Discovery Inc. |
Thiophene compound and application thereof
|
US20240165148A1
(en)
|
2021-03-15 |
2024-05-23 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
|
US11161833B1
(en)
|
2021-04-09 |
2021-11-02 |
Tremeau Pharmaceuticals, Inc. |
Deuterated etoricoxib, methods of manufacture, and use thereof
|
AU2022333323A1
(en)
|
2021-08-27 |
2024-02-29 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|